Is G.S.T. still active?

Yes, G.S.T. is currently active.

Where is G.S.T. registered?

G.S.T.'s registered address is Avenue Arnaud Fraiteur 15/23, 1050 Ixelles, Belgium.

How many employees does G.S.T. have?

Based on its most recently filed annual accounts (fiscal year ending 31 Dec 2025), G.S.T. reported 38.4 full-time equivalent employees.

What is G.S.T.'s annual turnover?

G.S.T.'s most recently filed annual turnover (fiscal year ending 31 Dec 2025) was €50,582,196.

Did G.S.T. make a profit or a loss?

G.S.T.'s most recently filed annual accounts (fiscal year ending 31 Dec 2025) reported a profit of €233,984.

When did G.S.T. last file annual accounts?

G.S.T.'s most recently filed annual accounts cover the fiscal year ending 31 Dec 2025.

Is G.S.T. B Corp certified?

We have no B Corp certification on file for G.S.T..

Does G.S.T. hold Fairtrade certification?

No, G.S.T. does not currently hold Fairtrade certification.

G.S.T.

Q: When was G.S.T. founded?

G.S.T. was founded on 08 Oct 1991, making it 34 years old.

Q: What does G.S.T. do?

G.S.T.'s registered main activities are Wholesale of pharmaceutical and medical goods, Systematic studies and creative efforts undertaken in various types of math research and development and natural sciences (physics, astronomy, chemistry, medical sciences, biology, etc.), Manufacture of medicaments, Care services for pet animals, other than veterinary, Manufacture of other pharmaceutical products, Manufacture of basic pharmaceutical products, Research and experimental development on other natural sciences and engineering, and Research and experimental development on biotechnology.

BE 0445.411.231

Copied!

NV/SA

Status

Active

Founded

08 Oct 1991 · 34 yrs

Size

Medium · 38.4 FTE

Legal name

Boehringer Ingelheim Animal Health Belgium SA

Main activity

Wholesale of pharmaceutical and medical goods

Activities

8 activities

Wholesale of pharmaceutical and medical goodsSystematic studies and creative efforts undertaken in various types of math research and development and natural sciences (physics, astronomy, chemistry, medical sciences, biology, etc.)Manufacture of medicamentsCare services for pet animals, other than veterinaryManufacture of other pharmaceutical productsManufacture of basic pharmaceutical productsResearch and experimental development on other natural sciences and engineeringResearch and experimental development on biotechnology

Financials

Turnover2025

€50.6M+8%

Profit / Loss2025

€234K-82.9%

Equity2025

€4.2M0%

2025	2024	2023	2022
€50,582,196+8%	€46,854,124+14.2%	€41,020,883+13.4%	€36,176,964
€233,984-82.9%	€1,372,451+74.2%	€787,896-21.5%	€1,003,522
€4,246,2530%	€4,246,2530%	€4,246,2530%	€4,246,253
€18,803,719+13%	€16,635,781+29.3%	€12,870,554+5.2%	€12,234,107
38.4-0.8%	38.7+1.6%	38.1+4.1%	36.6
€1,317,245+8.8%	€1,210,701+12.4%	€1,076,664+8.9%	€988,442

Frequently asked questions

01What is G.S.T.'s official registered name?

Boehringer Ingelheim Animal Health Belgium SA.

02What is G.S.T.'s enterprise number (VAT number)?

BE 0445.411.231.

03What is G.S.T.'s legal form?

Naamloze vennootschap (NV) / Société anonyme (SA).

04When was G.S.T. founded?

Sources

KBO — Kruispuntbank van Ondernemingen

NBB — Nationale Bank van België

Links

Belgian National Gazette — Publications

Check withholding obligation

Central Register of Director Disqualifications

	2025	2024	2023	2022
Income statement
	€50,582,196+8%	€46,854,124+14.2%	€41,020,883+13.4%	€36,176,964
	€5,687,367+3.6%	€5,488,400-1.6%	€5,575,834+16.4%	€4,789,461
	€723,197-66.5%	€2,161,888+58.4%	€1,364,964-19.1%	€1,686,421
	€1,805,439-32.3%	€2,665,200+53.4%	€1,737,362-17.1%	€2,096,017
	€1,330,226-28.1%	€1,850,763+36.2%	€1,358,512-0.9%	€1,371,118
	€233,984-82.9%	€1,372,451+74.2%	€787,896-21.5%	€1,003,522
	—	—	—	€49,706
Profitability
	3.6%-37.2%	5.7%+34.3%	4.2%-26.9%	5.8%
	0.5%-84.2%	2.9%+52.5%	1.9%-30.8%	2.8%
	5.5%-82.9%	32.3%+74.2%	18.6%-21.5%	23.6%
	1.0%-84.5%	6.3%+44.4%	4.3%-25.1%	5.8%
Solvency
	€24,038,190+10%	€21,856,251+20.7%	€18,116,025+4.8%	€17,281,359
	€2,279-74.2%	€8,820-41.3%	€15,032-32.1%	€22,128
	€4,246,2530%	€4,246,2530%	€4,246,2530%	€4,246,253
	17.7%-9.1%	19.4%-17.1%	23.4%-4.6%	24.6%
	€18,803,719+13%	€16,635,781+29.3%	€12,870,554+5.2%	€12,234,107
	4.43+13%	3.92+29.3%	3.03+5.2%	2.88
	20.10-98.1%	1085.22>1000%	42.26-92.2%	542.29
Liquidity
	€18,642,486+18.5%	€15,735,674+23%	€12,791,786-4%	€13,321,533
	€3,275,423+85.2%	€1,768,925+90.5%	€928,447-63.5%	€2,542,726
	€13,252,823-3.7%	€13,763,415+28.7%	€10,690,677+18.8%	€9,002,744
	€18,803,719+13%	€16,635,781+29.3%	€12,868,844+5.2%	€12,234,107
	1.28-2.7%	1.31-6.6%	1.41-0.3%	1.41
	€5,232,191+0.4%	€5,211,651-0.4%	€5,230,439+4.1%	€5,025,124
Efficiency
	24 days+71.6%	14 days+66.8%	8 days-67.8%	26 days
	111 days-14.4%	130 days+18.1%	110 days+2.2%	107 days
	214 days+3.4%	207 days+16.8%	177 days-13.3%	204 days
	1.85-5.1%	1.95-3.5%	2.02+7.5%	1.88
Profit appropriation
	€233,984-82.9%	€1,372,451+74.2%	€787,896-60.7%	€2,003,522
	€756,0700%	€756,0700%	€756,0700%	€756,070

Sources

NBB — Nationale Bank van België

	2025	2024	2023	2022
Income statement
	€50,582,196+8%	€46,854,124+14.2%	€41,020,883+13.4%	€36,176,964
	€5,687,367+3.6%	€5,488,400-1.6%	€5,575,834+16.4%	€4,789,461
	€723,197-66.5%	€2,161,888+58.4%	€1,364,964-19.1%	€1,686,421
	€1,805,439-32.3%	€2,665,200+53.4%	€1,737,362-17.1%	€2,096,017
	€1,330,226-28.1%	€1,850,763+36.2%	€1,358,512-0.9%	€1,371,118
	€233,984-82.9%	€1,372,451+74.2%	€787,896-21.5%	€1,003,522
	—	—	—	€49,706
Profitability
	3.6%-37.2%	5.7%+34.3%	4.2%-26.9%	5.8%
	0.5%-84.2%	2.9%+52.5%	1.9%-30.8%	2.8%
	5.5%-82.9%	32.3%+74.2%	18.6%-21.5%	23.6%
	1.0%-84.5%	6.3%+44.4%	4.3%-25.1%	5.8%
Solvency
	€24,038,190+10%	€21,856,251+20.7%	€18,116,025+4.8%	€17,281,359
	€2,279-74.2%	€8,820-41.3%	€15,032-32.1%	€22,128
	€4,246,2530%	€4,246,2530%	€4,246,2530%	€4,246,253
	17.7%-9.1%	19.4%-17.1%	23.4%-4.6%	24.6%
	€18,803,719+13%	€16,635,781+29.3%	€12,870,554+5.2%	€12,234,107
	4.43+13%	3.92+29.3%	3.03+5.2%	2.88
	20.10-98.1%	1085.22>1000%	42.26-92.2%	542.29
Liquidity
	€18,642,486+18.5%	€15,735,674+23%	€12,791,786-4%	€13,321,533
	€3,275,423+85.2%	€1,768,925+90.5%	€928,447-63.5%	€2,542,726
	€13,252,823-3.7%	€13,763,415+28.7%	€10,690,677+18.8%	€9,002,744
	€18,803,719+13%	€16,635,781+29.3%	€12,868,844+5.2%	€12,234,107
	1.28-2.7%	1.31-6.6%	1.41-0.3%	1.41
	€5,232,191+0.4%	€5,211,651-0.4%	€5,230,439+4.1%	€5,025,124
Efficiency
	24 days+71.6%	14 days+66.8%	8 days-67.8%	26 days
	111 days-14.4%	130 days+18.1%	110 days+2.2%	107 days
	214 days+3.4%	207 days+16.8%	177 days-13.3%	204 days
	1.85-5.1%	1.95-3.5%	2.02+7.5%	1.88
Profit appropriation
	€233,984-82.9%	€1,372,451+74.2%	€787,896-60.7%	€2,003,522
	€756,0700%	€756,0700%	€756,0700%	€756,070

2025

2024

2023

2022

Income statement

€50,582,196+8%

€46,854,124+14.2%

€41,020,883+13.4%

€36,176,964

€5,687,367+3.6%

€5,488,400-1.6%

€5,575,834+16.4%

€4,789,461

€723,197-66.5%

€2,161,888+58.4%

€1,364,964-19.1%

€1,686,421

€1,805,439-32.3%

€2,665,200+53.4%

€1,737,362-17.1%

€2,096,017

€1,330,226-28.1%

€1,850,763+36.2%

€1,358,512-0.9%

€1,371,118

€233,984-82.9%

€1,372,451+74.2%

€787,896-21.5%

€1,003,522

—

€49,706

Profitability

3.6%-37.2%

5.7%+34.3%

4.2%-26.9%

5.8%

0.5%-84.2%

2.9%+52.5%

1.9%-30.8%

2.8%

5.5%-82.9%

32.3%+74.2%

18.6%-21.5%

23.6%

1.0%-84.5%

6.3%+44.4%

4.3%-25.1%

5.8%

Solvency

€24,038,190+10%

€21,856,251+20.7%

€18,116,025+4.8%

€17,281,359

€2,279-74.2%

€8,820-41.3%

€15,032-32.1%

€22,128

€4,246,2530%

€4,246,253

17.7%-9.1%

19.4%-17.1%

23.4%-4.6%

24.6%

€18,803,719+13%

€16,635,781+29.3%

€12,870,554+5.2%

€12,234,107

4.43+13%

3.92+29.3%

3.03+5.2%

2.88

20.10-98.1%

1085.22>1000%

42.26-92.2%

542.29

Liquidity

€18,642,486+18.5%

€15,735,674+23%

€12,791,786-4%

€13,321,533

€3,275,423+85.2%

€1,768,925+90.5%

€928,447-63.5%

€2,542,726

€13,252,823-3.7%

€13,763,415+28.7%

€10,690,677+18.8%

€9,002,744

€18,803,719+13%

€16,635,781+29.3%

€12,868,844+5.2%

€12,234,107

1.28-2.7%

1.31-6.6%

1.41-0.3%

1.41

€5,232,191+0.4%

€5,211,651-0.4%

€5,230,439+4.1%

€5,025,124

Efficiency

24 days+71.6%

14 days+66.8%

8 days-67.8%

26 days

111 days-14.4%

130 days+18.1%

110 days+2.2%

107 days

214 days+3.4%

207 days+16.8%

177 days-13.3%

204 days

1.85-5.1%

1.95-3.5%

2.02+7.5%

1.88

Profit appropriation

€233,984-82.9%

€1,372,451+74.2%

€787,896-60.7%

€2,003,522

€756,0700%

€756,070

G.S.T.

Activities

Financials

Frequently asked questions

All locations

All locations